Low activity and remission in rheumatoid arthritis. Clinical, immunological and morphological aspects
https://doi.org/10.14412/1995-4484-2009-582
Abstract
Достижение стойкой клинической ремиссии при ревматоидном артрите (РА) за последние 10 лет стало реально достижимой задачей для практических ревматологов, в первую очередь в связи с внедрением современных методов терапии генно-инженерными биологическими препаратами (ГИБП) [1]. В случае своевременно установленного диагноза и рано начатой агрессивной терапии ремиссия или, как минимум, очень низкая активность болезни должна являться целью лечения [2].
References
1. <div><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита – современные рекомендации. Врач, 2007, 1, 38-41</p><p>Smolen J.S., Aletaha D., Machold K.P. Therapeutic strategies in early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol., 2005, 19, 163-77</p><p>Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматические болезни. Под. ред. Насоновой В.А., Бунчука Н.В., М., Медицина, 1997.с. 284</p><p>Гершанович М.Л. Основные принципы лечения неходжскинских лимфом. Практическая онкология, 2004, 5, 3, 185-93</p><p>Клинические рекомендации: Ревматология / под ред. Е.Л. Насонова, М., ГЭОТАР-МЕДИА, 2005. 288 с.</p><p>Pinals R.S., Masi A.T., Larsen R.A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum., 1981, 24, 1308–15</p><p>Prevoo M.L., van Gestel AM, van T Hof M et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol., 1996, 35, 1101-5</p><p>Fransen J., Creemers C.W., Van Riel P.L.C.M. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ACR preliminary remission criteria. Rheumatology, 2004, 1-4</p><p>Чемерис Н.А., Каратеев Д.Е., Насонов Е.Л. Новые подходы к оценке активности ревматоидного артрита: упрощенный индекс активности болезни SDAI (Simplified Disease Activity Index) при раннем артрите. Научно-практ. ревматол., 2005, 2, 7-13</p><p>Aletaha D., Smolen J.S. Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol., 2006, 24 (suppl. 43), S45-S51</p><p>Sokka T., Hetland M.L., Mäkinen H., et al. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. Arthritis Rheum., 2008, 58, 2642-51</p><p>Pincus T., Kavanaugh A., Aletaha D., Smolen J. Complexities in defining remission in rheumatic diseased. Clin. Exp. Rheumatol., 2006, 24 (suppl. 43), S1-S6</p><p>Каратеев Д.Е. Основные тенденции и вариабельность эволюции ревматоидного артрита: результаты многолетнего наблюдения. Научно-практич. ревматол., 2004, 1, 8-14</p><p>Mierau M., Schoels M., Gonda G. et al. Assessing remission in clinical practice. Rheumatology, 2007, 46, 975–9</p><p>Ревматология: Национальное руководство / под ред. Е.Л. Насонова, В.А. Насоновой. М., ГЭОТАР-МЕДИА, 2008, 720 с.</p><p>Mulherin D., Fitzgerald O., Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Brit. J. Rheumatol., 1996, 35, 1263-68</p><p>Lorber A., Simon T., Leeb J., Peter A., Wilcox S. Chrysotherapy. Suppression of immunoglobulin synthesis. Arthritis Rheum., 1978, 21, 7, 85-91.</p><p>Ревматоидный артрит. Под ред. В.А.Насоновой и В.Лайне. М., Медицина, 1983, 240 с.</p><p>Насонова В.А., Астапенко М.Г. Клиническая ревматология: Руководство для врачей. М., Медицина, 1989, 592 с.</p><p>Cush J.J., Jasin H.E., Johnson R., Lipsky P.E. Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. Arthritis Rheum., 1990, 33, 5, 623-33</p><p>Goodwin J.S., Ceuppens J.L., Rodriguez M.A. Administration of nonsteroidal anti-inflammatory agents in patients with rheumatoid arthritis. Effects on indexes of cellular immune status and serum rheumatoid factor levels. JAMA, 1983, 250, 18, 2485-8</p><p>Olsen N.J., Teal G.P., Brooks R.H. IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. Agents Actions, 1991, 34, 169-71</p><p>Dougados M., Awada H., Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann. Rheum. Dis., 1988, 47, 2, 127-33</p><p>Furst D.E. Rational use of disease-modifying antirheumatic drugs. Drugs, 1990, 39, 1,19-37</p><p>Horneff G., Burmester G.R., Emmrich F., Kalden J.R. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum., 1991, 34, 2, 129-40</p><p>Bobbio-Pallavicini F., Alpini C., Caporali R., Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 2004, 6, R264-272.</p><p>Nissinen R., Leirisalo-Repo M., Peltomaa R., Palosuo T, Vaarala O. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Ann. Rheum. Dis., 2004, 3, 681-7.</p><p>Alessandri C., Bombardieri M., Papa N., et al. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis. 2004, 63, 1218-21.</p><p>Caramaschi P., Biasi D., Tonolli E., et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int., 2005, 26, 58-62.</p><p>De Rycke L., Verhelst X., Kruithof E., et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide anti- bodies, is modulated by infliximab treatment in rheu- matoid arthritis. Ann. Rheum. Dis., 2005,64, 299-302</p><p>Yazdani-Biuki B., Stadlmaier E., Mulabecirovic A., et al. Blockade of tumour necrosis factor (alpha) significantly alters the serum level of IgG- and IgA- rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2005, 64, 1224-6.</p><p>Braun-Moscovici Y., Markovits D., Zinder O., et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J. Rheumatol., 2006, 33, 497-500.</p><p>Chen H.A., Lin K.C., Chen C.H., et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2006, 65, 35-9.</p><p>Atzeni F., Sarzi-Puttini P., Dell’ Acqua D., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res. Ther., 2006, 8, R3.</p><p>Ahmed M.M., Mubashir E., Wolf R.E., et al. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis. South Med. J., 2006, 99, 1209-15.</p><p>Bobbio-Pallavicini F., Caporali R., Alpini C., et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann. Rheum. Dis., 2007, 66, 302-7</p><p>Vis M., Bos W.H., Wolbink G., et al. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. J. Rheumatol., 2008, 35, 425-8.</p><p>Bobbio-Pallavicini F., Caporali R., Bugatti S., Montecucco C. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? J. Rheumatol., 2008, 35, 10, 1903-6</p><p>Bacquet-Deschryver H., Jouen F., Quillard M. et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J. Clin. Immunol., 2008, 28, 5, 445-55.</p><p>Roland P.N., Mignot S.G., Bruns A., et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthr. Res. Ther.,2008, 10, 6, R142</p><p>Onno Teng Y.K., Nivine Levarht E.W., Mojtaba Hashem et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum., 2007, 56, 12, 3909–18</p><p>McGonagle D., Tan A.L., Madden J., Taylor L., Emery P. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford)., 2008, 47, 6, 865-7</p><p>Toubi E., Kessel A., Slobodin G. et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2007, 66, 6, 818-20</p><p>Копьева Т.Н., Веникова М.С. Клиническая морфология артритов при ревматических заболеваниях, М., Медицина, 1992, 219 с.</p><p>Чичасова Н.В., Шехтер А.Б., Крель А.А. Эволюция морфологических проявлений синовита с начальной стадией ревматоидного артрита при различных вариантах его дальнейшего течения. Ревматология, 1988, 2, 3–16</p><p>Bresnihan B., Tak P.P., Emery P., et al. Synovial biopsy in arthritis research: five years of concerted European collaboration. Ann. Rheum. Dis., 2000, 59, 506–10</p><p>Cunnane G., Bjork L., Ulfgren A.-K., et al. Quantitative analysis of synovial membrane inflammation: a com- parison between automated and conventional microscopic measurements. Ann. Rheum. Dis.,1999, 58, 8, 493-9</p><p>Ostergaard M., Pedersen S.J., Dohn U.M. Imaging in rheumatoid arthritis - status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res. Clin. Rheumatol., 2008, 22, 1019-44</p><p>Bliddal H., Boesen M., Christensen R., Kubassova O., Torp-Pedersen S. Imaging as a follow-up tool in clinical trials and clinical practice. Best Pract Res. Clin. 11 Rheumatol., 2008, 22, 6,1109-26.</p><p>Ellegaard K., Torp-Pedersen S., Terslev L., Danneskiold-Samsøe B., Henriksen M., Bliddal H. Ultrasound colour Doppler measurements in a single joint as measure of disease activity in patients with rheumatoid arthritis - assessment of concurrent validity. Rheumatology (Oxford), 2009, doi: 10.1093/rheumatology/ken459</p><p>Voulgari P.V., Alamanos Y., Drosos A.A. Persistent clinical response of infliximab therapy in patients with refractory rheumatoid arthritis, over a 3-year period. Curr. Clin. Pharmacol. 2006, 1, 1, 103-8</p><p>Tam L.S., Griffith J.F., Yu A.B., Li T.K., Li E.K. Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation. Clin. Rheumatol. 2007, 26, 6, 941-6</p><p>Quinn M.A., Conaghan P., O’Connor P. et al. Very Early Treatment With Infliximab in Addition to Methotrexate in Early, Poor-Prognosis Rheumatoid Arthritis Reduces Magnetic Resonance Imaging Evidence of Synovitis and Damage, With Sustained Benefit After Infliximab Withdrawal Arthritis Rheum., 2005, 52,1, 27–35</p><p>Durez P., Malghem J., Nzeusseu Toukap A. et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in com- bination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum., 2007, 56, 12, 3919-27</p><p>Østergaard M., Duer A., Nielsen H. et al. Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment. Ann. Rheum. Dis., 2005, 64, 10, 1503-6</p><p>Grigor C., Capell H., Stirling A. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet, 2004, 364(9430), 263-9.</p><p>Hetland M.L., Ejbjerg B.J., Hørslev-Petersen K. et al., MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA). Ann. Rheum. Dis., 2008, Apr 3. [Epub ahead of print]</p><p>Brown A.K., Conaghan P.G., Karim Z., et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum., 2008, 58, 2958-67.</p><p>St. Clair E.W., van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum., 2004, 11, 3432-43</p><p>Smolen J.S., Han C., Bala M. et al. Evidence of radiographic benefit of treatment with infliximab plus</p><p>methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. ArthritisRheum., 2005, 52, 4, 1020-30</p><p>Taylor P.C., Steuer A., Gruber J. et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum., 2006, 54, 1, 47-53</p><p>Montecucco C. Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies. Drugs, 2006, 66, 14, 1783-95</p><p>Каратеев Д.Е. Современные возможности достижения клинической ремиссии при ревматоидном артрите. Трудный пациент, 2007, 5, 11, 45-48</p><p>Sesin C.A., Bingham C.O. 3rd. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum., 2005, 35, 3, 185-96</p><p>Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М., ГЭОТАР-Медиа, 2006.</p><p>Fautrel B., Pham T., Mouterde G., et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist ther- apy in patients with rheumatoid arthritis. Joint Bone Spine, 2007, 74, 627-37</p><p>Saleem B., Nizam S., Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin. Exp. Rheumatol., 2006, 24, 6, suppl. 43, S-33-36</p><p>Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., Allaart C.F.et al. Clinical and radiographic outcomes of four different treatment strategies in Patients With Early Rheumatoid Arthritis (the BeSt Study). Arthritis Rheum., 2005, 11, 3381-90</p><p>Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., Allaart C.F.et al. Comparison of treatment strategies in early rheumatoid arthritis. A randomized trial. Ann. Intern. Med., 2007, 146, 406-15</p><p>Van der Kooij S.M., Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K et al. Clinical and radiological efficacy in fourth different treatment strategies in Patients With Early Rheumatoid Arthritis: 3-year follow-up of the BeSt Study. Ann. Rheum. Dis. 2007, 66(suppl II), 91</p><p>Van der Kooij S.M., Allaart C.F, de Vries-Bouwstra J.K et al. Remission induction in Early Rheumatoid Arthritis with initial infliximab and metotrexate therapy: 4-year follow-up data of the disease course after infliximab discontinuation in the BeSt trial. Ann. Rheum. Dis., 2007, 66(suppl II), 192</p><p>Allaart C.F., Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp. Rheumatol., 2006, 24 (suppl. 43), S77-S82</p><p>Van der Bijl A. E., Goekoop-Ruiterman Y. P. M., de Vries-Bouwstra J. K. et al. Infliximab and Methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum., 2007, 56, 7, 2129–34</p><p>Klarenbeek N.B., Güler-Yüksel M., van der Kooij S.M. et al. Clinical outcomes of four different treat- ment stretegies in patients with recent-onset rheumatoid arthritis: 5-years results of the BeSt-study. Ann. Rheum. Dis., 2008, 67(suppl II),187</p></div><br />
Review
For citations:
Karateev D.E. Low activity and remission in rheumatoid arthritis. Clinical, immunological and morphological aspects. Rheumatology Science and Practice. 2009;47(5):4-12. (In Russ.) https://doi.org/10.14412/1995-4484-2009-582
Views:
1251
Email this article 